Sponsors / SPRY
SPRY

ARS Pharmaceuticals, Inc.

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
3Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Administration of ARS-1 or Albuterol in Subjects With Persistent AsthmaNCT05363670SPRYPhase 2Completed2024-02-02Actual
Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria FlaresNCT05496465SPRYPhase 2Completed2024-02-29Actual
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous UrticariaNCT06927999SPRYPhase 2Recruiting2027-06Estimated

Latest recorded trial changes

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

NCT06927999 · ARS Pharmaceuticals, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch and hive

+ Updated value

measure: Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

NCT05496465 · ARS Pharmaceuticals, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Effect of ARS-1 versus placebo based on a patient reported pruritus/hive score

+ Updated value

measure: Effect of ARS-1 Versus Placebo Based on a Patient Reported Pruritus/Hive Score

Check registry source · The saved outcome text may be shortened. Check the source for full wording.